## Samer Al-Saad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8956247/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 5220-5227.	3.2	547
2	The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 209-217.	0.5	502
3	The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 824-833.	0.5	276
4	Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2635-2643.	3.2	269
5	The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. British Journal of Cancer, 2008, 99, 1476-1483.	2.9	119
6	Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia, 2019, 21, 282-293.	2.3	117
7	Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer. Cancer, 2010, 116, 5676-5685.	2.0	115
8	Prognostic Impact of Platelet-Derived Growth Factors in Non-small Cell Lung Cancer Tumor and Stromal Cells. Journal of Thoracic Oncology, 2008, 3, 963-970.	0.5	100
9	Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 6649-6657.	3.2	99
10	The prognostic value of intraepithelial and stromal innate immune system cells in nonâ€small cell lung carcinoma. Histopathology, 2009, 55, 301-312.	1.6	95
11	Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate, 2014, 74, 1452-1461.	1.2	95
12	Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization. Journal of Translational Medicine, 2011, 9, 6.	1.8	92
13	MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer. PLoS ONE, 2012, 7, e29671.	1.1	87
14	Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer, 2017, 18, 220-233.e8.	1.1	72
15	Independent and tissueâ€specific prognostic impact of miRâ€126 in nonsmall cell lung cancer. Cancer, 2011, 117, 3193-3200.	2.0	67
16	Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival. Journal of Thoracic Oncology, 2009, 4, 578-585.	0.5	64
17	CD45RO+ Memory T Lymphocytes — a Candidate Marker for TNM-Immunoscore in Squamous Non–Small Cell Lung Cancer. Neoplasia, 2015, 17, 839-848.	2.3	62
18	Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers. PLoS ONE, 2015, 10, e0134965.	1.1	61

SAMER AL-SAAD

#	Article	IF	CITATIONS
19	Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival. PLoS ONE, 2014, 9, e105038.	1.1	59
20	Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer. Oncotarget, 2016, 7, 72184-72196.	0.8	54
21	Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer, 2014, 83, 272-278.	0.9	53
22	Overexpression of the HIF Hydroxylases PHD1, PHD2, PHD3 and FIH Are Individually and Collectively Unfavorable Prognosticators for NSCLC Survival. PLoS ONE, 2011, 6, e23847.	1.1	52
23	Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non–small cell lung cancer. Human Pathology, 2018, 79, 188-198.	1.1	49
24	Combination of low vascular endothelial growth factor A (VEGFâ€A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer, 2010, 116, 4318-4325.	2.0	48
25	LAG-3 in Non–Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival. Clinical Lung Cancer, 2018, 19, 249-259.e2.	1.1	48
26	The prognostic value of intraepithelial and stromal CD3â€, CD117―and CD138â€positive cells in nonâ€small cell lung carcinoma. Apmis, 2010, 118, 371-382.	0.9	45
27	CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer, 2013, 80, 209-215.	0.9	45
28	Cancer-Associated Fibroblasts from Lung Tumors Maintain Their Immunosuppressive Abilities after High-Dose Irradiation. Frontiers in Oncology, 2015, 5, 87.	1.3	45
29	Stromal Expression of MiR-21 Predicts Biochemical Failure in Prostate Cancer Patients with Gleason Score 6. PLoS ONE, 2014, 9, e113039.	1.1	44
30	Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer. Steroids, 2016, 113, 5-13.	0.8	44
31	MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Scientific Reports, 2019, 9, 386.	1.6	43
32	High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure. PLoS ONE, 2015, 10, e0116691.	1.1	42
33	Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer, 2011, 72, 294-302.	0.9	40
34	Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS ONE, 2017, 12, e0186852.	1.1	39
35	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 2021, 124, 1680-1689.	2.9	37
36	Stage and tissue-specific prognostic impact of miR-182 in NSCLC. BMC Cancer, 2014, 14, 138.	1.1	34

SAMER AL-SAAD

#	Article	IF	CITATIONS
37	Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression. Scientific Reports, 2018, 8, 11358.	1.6	34
38	Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer, 2015, 15, 441.	1.1	31
39	Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Research, 2009, 29, 4175-83.	0.5	31
40	Prognostic Impacts of Angiopoietins in NSCLC Tumor Cells and Stroma: VEGF-A Impact Is Strongly Associated with Ang-2. PLoS ONE, 2011, 6, e19773.	1.1	30
41	Estrogen receptors $\hat{l}\pm$ and $\hat{l}^2$ and aromatase as independent predictors for prostate cancer outcome. Scientific Reports, 2016, 6, 33114.	1.6	30
42	Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy. Journal of Thoracic Oncology, 2009, 4, 463-471.	0.5	29
43	The Prognostic Significance of CXCL16 and Its Receptor C-X-C Chemokine Receptor 6 in Prostate Cancer. American Journal of Pathology, 2015, 185, 2722-2730.	1.9	27
44	Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: Correlation with a favorable clinical outcome. Lung Cancer, 2012, 75, 235-241.	0.9	25
45	Stromal expression of VEGFâ€A and VEGFRâ€2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy. Prostate, 2015, 75, 1682-1693.	1.2	25
46	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. British Journal of Cancer, 2016, 114, 1145-1151.	2.9	25
47	VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: Inverse correlation between expression in tumor and stromal cells. Lung Cancer, 2009, 63, 277-283.	0.9	24
48	A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Scientific Reports, 2018, 8, 8549.	1.6	24
49	Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size. Clinical Lung Cancer, 2011, 12, 106-115.	1.1	23
50	The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival. Steroids, 2015, 98, 29-36.	0.8	22
51	Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients. Journal of Thoracic Oncology, 2010, 5, 1536-1543.	0.5	20
52	High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome. BMC Clinical Pathology, 2014, 14, 9.	1.8	20
53	The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer. PLoS ONE, 2017, 12, e0181527.	1.1	18
54	Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer. Scientific Reports, 2018, 8, 5059.	1.6	11

#	Article	IF	CITATIONS
55	Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer. Acta Oncológica, 2016, 55, 167-177.	0.8	8
56	Isoflurane Increases Tolerance to Renal Ischemia Reperfusion Injury Compared to Propofol: An Experimental Study in Pigs. Journal of Investigative Surgery, 2021, 34, 359-365.	0.6	1